CD226 and cancer: Secondly, in addition to inhibiting cancer cells through single-chain antibody recognition of tumor surface antigens, NK cells can also recognize various ligands through multiple receptors such as NCRs (NKp46, NKp44, and NKp30), NKG2D, and DNAM-1 (CD226) [69–71].